WallStreetZenWallStreetZen

NASDAQ: FENC
Fennec Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for FENC

Based on 5 analysts offering 12 month price targets for Fennec Pharmaceuticals Inc.
Min Forecast
$11.00+14.94%
Avg Forecast
$14.80+54.65%
Max Forecast
$19.00+98.54%

Should I buy or sell FENC stock?

Based on 5 analysts offering ratings for Fennec Pharmaceuticals Inc.
Buy
Strong Buy
1 analysts 20%
Buy
4 analysts 80%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their FENC stock forecasts and price targets.

FENC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Cantor Fitzgerald
Top 2%
99
Strong BuyUpgrades$12.00+25.39%2022-11-22Find out why
HC Wainwright & Co.
Bottom 1%
1
BuyMaintains$18.00+88.09%2022-10-20
Wedbush
Top 4%
97
BuyMaintains$19.00+98.54%2022-09-26
Capital One Financial
Bottom 8%
8
BuyInitiates Coverage On$11.00+14.94%2022-09-07
Craig-Hallum
Top 44%
57
BuyAssumes$14.00+46.29%2022-08-08

1 of 1

Forecast return on equity

Is FENC forecast to generate an efficient return?
Company
917.66%
Industry
14.42%
Market
62.81%
FENC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is FENC forecast to generate an efficient return on assets?
Company
84.53%
Industry
13.43%
FENC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

FENC earnings per share forecast

What is FENC's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$0.58
Avg 2 year Forecast
-$0.38
Avg 3 year Forecast
$0.38

FENC revenue forecast

What is FENC's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$3.0M
Avg 2 year Forecast
$25.1M
Avg 3 year Forecast
$42.5M

FENC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
FENC$9.57$14.80+54.65%Buy
VAXX$1.98$19.50+884.85%Strong Buy
DBVT$1.31$7.50+472.52%Buy
CELU$1.69$10.00+491.72%Buy
PDSB$9.03$16.00+77.19%Strong Buy

Fennec Pharmaceuticals Stock Forecast FAQ

Is Fennec Pharmaceuticals Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: FENC) stock is to Buy FENC stock.

Out of 5 analysts, 1 (20%) are recommending FENC as a Strong Buy, 4 (80%) are recommending FENC as a Buy, 0 (0%) are recommending FENC as a Hold, 0 (0%) are recommending FENC as a Sell, and 0 (0%) are recommending FENC as a Strong Sell.

If you're new to stock investing, here's how to buy Fennec Pharmaceuticals stock.

What is FENC's earnings growth forecast for 2022-2024?

(NASDAQ: FENC) Fennec Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 7.88%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.01%.

Fennec Pharmaceuticals's earnings in 2022 is -$21,284,000.On average, 2 Wall Street analysts forecast FENC's earnings for 2022 to be -$15,217,881, with the lowest FENC earnings forecast at -$16,005,013, and the highest FENC earnings forecast at -$14,430,749. On average, 2 Wall Street analysts forecast FENC's earnings for 2023 to be -$9,970,336, with the lowest FENC earnings forecast at -$18,891,163, and the highest FENC earnings forecast at -$1,049,509.

In 2024, FENC is forecast to generate $9,970,336 in earnings, with the lowest earnings forecast at $9,970,336 and the highest earnings forecast at $9,970,336.

What is FENC's revenue growth forecast for 2022-2024?

(NASDAQ: FENC) Fennec Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 25.1%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 6.74%.

Fennec Pharmaceuticals's revenue in 2022 is $0.On average, 1 Wall Street analysts forecast FENC's revenue for 2022 to be $78,450,801, with the lowest FENC revenue forecast at $78,450,801, and the highest FENC revenue forecast at $78,450,801. On average, 1 Wall Street analysts forecast FENC's revenue for 2023 to be $658,042,168, with the lowest FENC revenue forecast at $658,042,168, and the highest FENC revenue forecast at $658,042,168.

In 2024, FENC is forecast to generate $1,115,628,110 in revenue, with the lowest revenue forecast at $1,115,628,110 and the highest revenue forecast at $1,115,628,110.

What is FENC's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: FENC) forecast ROA is 84.53%, which is higher than the forecast US Biotechnology industry average of 13.43%.

What is FENC's Price Target?

According to 5 Wall Street analysts that have issued a 1 year FENC price target, the average FENC price target is $14.80, with the highest FENC stock price forecast at $19.00 and the lowest FENC stock price forecast at $11.00.

On average, Wall Street analysts predict that Fennec Pharmaceuticals's share price could reach $14.80 by Nov 22, 2023. The average Fennec Pharmaceuticals stock price prediction forecasts a potential upside of 54.65% from the current FENC share price of $9.57.

What is FENC's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: FENC) Fennec Pharmaceuticals's current Earnings Per Share (EPS) is -$0.81. On average, analysts forecast that FENC's EPS will be -$0.58 for 2022, with the lowest EPS forecast at -$0.61, and the highest EPS forecast at -$0.55. On average, analysts forecast that FENC's EPS will be -$0.38 for 2023, with the lowest EPS forecast at -$0.72, and the highest EPS forecast at -$0.04. In 2024, FENC's EPS is forecast to hit $0.38 (min: $0.38, max: $0.38).

What is FENC's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: FENC) forecast ROE is 917.66%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.